Sinh học thần kinh của rối loạn lưỡng cực: Ý nghĩa cho nghiên cứu và điều trị trong tương lai

Post RM, Stoddard FJ, Gillin JC, Buchsbaum MS, Runkle DC, Black KE, Bunney WEJ: Alterations in motor activity, sleep, and biochemistry in a cycling manic–depressive patient. Arch Gen Psychiatry 1977; 34:470-477 Jimerson DC, Nurnberger JI, Jr, Post RM, Gershon ES, Kopin IJ: Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry 1981; 38:1287-1290 Rubinow DR, Post RM, Pickar D, Naber D, Ballenger JC, Gold PW, Bunney WE: Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Res 1981; 5:87-93 Rubinow DR, Post RM, Gold PW, Ballenger JC, Wolff EA: The relationship between cortisol and clinical phenomenology of affective illness. In Post RM, Ballenger JC eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins; 1984:271-289 Swann AC, Stokes PE, Casper R, Secunda SK, Bowden CL, Berman N, Katz MM, Robins E: Hypothalamic–pituitary–adrenocortical function in mixed and pure mania. Acta Psychiatr Scand 1992; 85:270-274 Banki CM, Karmacsi L, Bissette G, Nemeroff CB: CSF corticotropin-releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992; 2:107-113 Owens MJ, Nemeroff CB: The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: Laboratory and clinical studies. Ciba Found Symp. 1993; 172:296-308 Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJJ, May C, Post RM, Chrousos GP, Gold PW: Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushings disease and major depression: Potential clinical implications. J Clin Endocrinol Metab 1991; 72:260-271 Rubinow DR, Gold PW, Post RM, Ballenger JC, Cowdry R, Bollinger J, Reichlin S: CSF somatostatin in affective illness. Arch Gen Psychiatry 1983; 40:409-412 Rubinow DR, Davis CL, Post RM: Somatostatin in neuropsychiatric disorders. In Weil C, Muller EE, Thorner MO eds. Basic and Clinical Aspects of Neuroscience, Vol. 4. Berlin/Heidelberg, Springer-Verlag; 1992:29-42 Ongur D, Drevets WC, Price JL: Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95:13290-13295 Bowley M, Drevets W, Ongur D, Price J: Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002; 52:404 Rajkowska G: Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48:766-777 Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM: Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry 2001; 49:97-109 Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, Post RM: Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry 2002; 51:387-399 Benson, BE, Willis, MW, Ketter, TA, Kimbrell, TA, Osuch, EA, Speer, AM, and Post, RM: Altered relationships in rCMRglu associativity in bipolar and unipolar illness. Biol Psychiatry 2000; 47(8S):108S. Alexander GE, Crutcher MD, Delong MR: Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res 1990; 85:119-146 Ketter TA, Kimbrell TA, George MS, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM: Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Biol Psychiatry 1999; 46:1364-1374 Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S: Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology (Berl) 1985; 85:210-213 Pazzaglia PJ, George MS, Post RM, Rubinow DR, Davis CL: Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology 1995; 13:75-83 Frye MA, Pazzaglia PJ, George MS, Luckenbaugh D, Vanderham E, Davis CL, Rubinow DR, and Post RM: Low CSF somatostatin associated with response to nimodipine in patients with affective illness. Biol Psychiatry 2003; 53:180-183 Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, Luckenbaugh D: Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18:404-413 Dubovsky SL, Lee C, Christiano J, Murphy J: Elevated platelet intracellular calcium concentration in bipolar depression. Biol Psychiatry 1991; 29:441-450 Post RM, Pazzaglia PJ, Ketter TA, Denicoff K, Weiss SRB, Hough C, Chuang D-M, Stein R, Frye M: Carbamazepine and nimodipine in refractory affective illness. In Halbreich U, Montgomery S eds. Efficacy and mechanisms in Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders. Washington, DC: American Psychiatric Press: 2000:77-110 Emamghoreishi M, Schlichter L, Li PP, Parikh S, Sen J, Kamble A, Warsh JJ: High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 1997; 154:976-982 Torrey EF, Webster M, Knable M, Johnston N, Yolken RH: The Stanley Foundation brain collection and neuropathology consortium. Schizophr Res 2000; 44:151-155 Knable MB, Torrey EF, Webster MJ, Bartko JJ: Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001; 55:651-659 Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, Kanai H, Hough C, Hiroi T, Leeds P: Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002; 4:129-136 Manji HK, Moore GJ, Chen G: Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilisers. Br J Psychiatry 2001; 178:S107-S119 Ahrens B, Muller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K: Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33:67-75 Nonaka S, Katsube N, Chuang DM: Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 1998; 286:539-547 Nonaka S, Hough CJ, Chuang DM: Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998; 95:2642-2647 Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72:879-882 Chen RW, Chuang DM: Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274:6039-6042 Nonaka S, Chuang DM: Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9:2081-2084 Wei H, Qin Z, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang D: Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001; 106:603-612 Muller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, Simhandl C, Thau K, Volk J, Wolf R: The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86:218-222 Muller-Oerlinghausen B, Muser-Causemann B, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25:261-269 Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E: Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch Gen Psychiatry 2000; 57:1061-1069 Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998; 95:15718-15723 Xing GQ, Russell S, Hough C, O'Grady J, Zhang L, Yang S, Zhang LX, Post RM: Decreased prefrontal CaMKII α mRNA in bipolar illness. Neuroreport 2002; 13:501-505 Frankland PW, O'Brien C, Ohno M, Kirkwood A, Silva AJ: Alpha-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature 2001; 411:309-313 Silva AJ, Stevens CF, Tonegawa S, Wang Y: Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science 1992; 257:201-206 Post RM, Denicoff KD, Leverich GS, Huggins T, Post SW, Luckenbaugh D: Neuropsychological deficits of primary affective illness: Implications of therapy. Psychiatr Ann 2000; 30:485-494 Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G: Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000; 48:861-873 Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH: Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000; 5:142-149 Eastwood SL, Harrison PJ: Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: A study of complexin mRNAs. Mol Psychiatry 2000; 5:425-432 Ali SO, Denicoff KD, Altshuler LL, Hauser P, Li X, Conrad AJ, Mirsky AF, Smith-Jackson EE, Post RM: A preliminary study of the relation of neuropsychological perfomance to neuroanatomic structures in bipolar disorder. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:20-28 Ali SO, Denicoff KD, Altshuler LL, Hauser P, Li X, Conrad AJ, Smith-Jackson EE, Leverich GS, Post RM: Relationship between prior course of illness and neuroanatomic structures in bipolar disorder: A preliminary study. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:227-232. Altshuler LL, Bartzokis G, Grieder T, Curran J, Mintz J: Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: An MRI study demonstrating neuroanatomic specificity [Letter]. Arch Gen Psychiatry 1998; 55:663-664 Strakowski SM, DelBello MP, Sax KW, Zimmerman ME, Shear PK, Hawkins JM, Larson ER: Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 1999; 56:254-260 Brambilla P, Harenski K, Nicoletti M, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC: Are amygdala volumes increased in bipolar disorder patients? Bipolar Disord 2001; 3:28 Pearlson GD, Barta PE, Powers RE, Menon RR, Richards SS, Aylward EH, Federman EB, Chase GA, Petty RG, Tien AY: Ziskind-Somerfeld Research Award 1996. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biol Psychiatry 1997; 41:1-14 Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME: Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 2002; 71:431-447 George MS, Ketter TA, Parekh PI, Gill DS, Marangell L, Pazzaglia PJ, Herscovitch P, Post RM: Depressed subjects have decreased rCBF activation during facial emotion recognition. CNS Spectrums 1997; 2:45-55 Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE, Jr, Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA: High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 2002; 51:305-311 Schmahmann JD, Sherman JC: The cerebellar cognitive affective syndrome. Brain 1998; 121:561-579 Gold PW, Kling MA, Khan I, Calabrese JR, Kalogeras K, Post RM, Avgerinos PC, Loriaux DL, Chrousos GP: Corticotropin releasing hormone: Relevance to normal physiology and to the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency. Adv Biochem Psychopharmacol 1987; 43:183-200 Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L'Herrou TA, Leverich GS, Post RM: Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997; 54:214-222 Speer AM, Kimbrell TA, Wassermann EM, Repella D, Willis MW, Herscovitch P, Post RM: Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry 2000; 48:1133-1141 Anisman H, Zaharia MD, Meaney MJ, Merali Z: Do early-life events permanently alter behavioral and hormonal responses to stressors? Int J Dev Neurosci 1998; 16:149-164 Plotsky PM, Meaney MJ: Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Mol Brain Res 1993; 18:195-200 Zhang LX, Levine S, Dent G, Zhan Y, Xing G, Okimoto D, Kathleen GM, Post RM, Smith MA: Maternal deprivation increases cell death in the infant rat brain. Brain Res Dev Brain Res 2002; 133:1-11 Riley JH, Allan CJ, Lai E, Roses A: The use of single nucleotide polymorphisms in the isolation of common disease genes. Pharmacogenomics 2000; 1:39-47